双醋瑞因联合独活寄生汤治疗中老年膝骨性关节炎

目的:评价双醋瑞因联合独活寄生汤治疗中老年膝骨性关节炎的临床疗效和安全性。方法:将确诊为膝骨性关节炎患者120例随机分为A,B,C 3组,A组为独活寄生汤组,B组为双醋瑞因组,C组为独活寄生汤联合双醋瑞因组,分别采用相应治疗。3组均以1个月为1个疗程,共观察、治疗3个疗程。以VAS评分、WOMAC评分、红细胞沉降率(ESR),C反应蛋白(CRP)治疗前后变化作为临床疗效判定指标,并对综合疗效评分做出评价,观察治疗过程中不良反应例数。结果:3个月治疗后,3组VAS评分,WOMAC评分,ESR,CRP均较治疗前有显著改善(P<0.01),C组临床疗效指标改善情况要优于药物单用的B和C组(P<0.05),且综合疗效评价效果较好(P<0.01),且具有较低的不良反应率(7.5%)。结论:双醋瑞因、独活寄生汤是治疗膝骨关节炎的有效药物,临床疗效良好,联合使用效果更为显著,且无明显不良反应,值得推广。

Clinical Observation of Diacerein Combined with Duhuo Jisheng Decoction in Treatment of Middle-old People with Knee Osteoarthritis

Objective: To approach the curative effect and safety of Diacerein combined with Duhuo Jisheng decoction in the treatment of knee osteoarthritis. Method: One hundred and twenty patients with knee osteoarthritis were selected, which were divided into Duhuo Jisheng decoction group (group A), Diacerein group (group B) and combination group (group C) randomLy. Every group was handled with the appropriate treatment. One month was a course, and totally with observation and treatment of three month. The VAS score, WOMAC score, ESR and CRP were the indicators of clinical efficacy, and the comprehensive efficacy score was evaluated. Result: After the treatment for three months, the VAS score, WOMAC score, erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP) were improved significantly than before(P<0.01).The indicators of clinical efficacy in group C were better the group B and C(P<0.05), the comprehensive efficacy score were also best(P<0.01), and with a lower rate of adverse events(7.5%). Conclusion: Diacerein and Duhuo Jisheng decoction were effective drugs for treatment of the knee osteoarthritis; the clinical efficacy was more significant when combined together, and with no obvious adverse events. It is worth promoting.